CSIMarket
 
Inflarx N v   (IFRX)
Other Ticker:  
 
 
Price: $1.5800 $0.06 3.947%
Day's High: $1.615 Week Perf: -2.47 %
Day's Low: $ 1.49 30 Day Perf: 7.48 %
Volume (M): 124 52 Wk High: $ 7.25
Volume (M$): $ 196 52 Wk Avg: $2.92
Open: $1.50 52 Wk Low: $1.14



 Market Capitalization (Millions $) 70
 Shares Outstanding (Millions) 44
 Employees 100
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 0

Inflarx N V
InflaRx N.V. is a clinical-stage biopharmaceutical company that focuses on discovering and developing first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and small molecule inhibitors of C5aR. They aim to address a wide range of complement-mediated diseases with significant unmet medical needs, including severe COVID-19, pyoderma gangrenosum, hidradenitis suppurativa, and ANCA-associated vasculitis. InflaRx's lead product candidate is vilobelimab, a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. They are also developing IFX002, a life-cycle management product for vilobelimab, and INF904, an orally administered, small-molecule inhibitor of C5aR. InflaRx was founded in 2007 as InflaRx GmbH by Professor Niels Riedemann and Professor Renfeng Guo in Jena, Germany. The company employs a total of 48 employees, 18 of whom have M.D. or Ph.D. degrees. The company's management team has extensive experience in the field of complement research, clinical research, and the biopharmaceutical industry.


   Company Address: Winzerlaer Str. 2 Jena 0
   Company Phone Number: (3641) 508 180   Stock Exchange / Ticker: NASDAQ IFRX
   IFRX is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

HeadlineBiopharmaceutical Company, InflaRx Pharmaceuticals, Launches Commitment Program to Improve Access to GOHIBIC for COVID-19 Patients

Published Thu, Jan 25 2024 12:30 PM UTC

InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V., a biopharmaceutical company specializing in anti-inflammatory therapeutics targeting the complement system, has recently introduced the InflaRx Commitment Program. This program aims to broaden access to their product GOHIBIC (vilobelimab) for eligible patients. Under this program, institutions that meet the eligibil...

Clinical Study

Unveiling the Promise: InflaRx's INF904 Sets New Benchmarks as a Best-in-Class C5aR Inhibitor

Published Thu, Jan 4 2024 12:00 PM UTC

Inflammation is a complex immune response that plays a crucial role in various diseases, including autoimmune disorders. Targeting the complement system, a key mediator of inflammation, has emerged as a promising therapeutic strategy. InflaRx N.V., a biotechnology company focused on developing anti-inflammatory therapeutics, recently announced positive topline results from t...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com